{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:26:39Z","timestamp":1791505599228,"version":"4.3.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore mental health service user attitudes to psychedelics and psilocybin therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A questionnaire capturing demographics, diagnoses, previous psychedelic and other drug use, and attitudes to psychedelics and psilocybin therapy was distributed to mental health service users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-nine participants completed the survey (52% female, mean age 42\u00a0years). The majority (72%) supported further research, with 59% supporting psilocybin as a medical treatment. A total of\u00a027% previously used recreational psilocybin, with a male preponderance (p\u2009=\u20090.01). Younger age groups, those with previous psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin. A total of 55% of the total sample would accept as a treatment if doctor recommended, whereas 20% would not. Fewer people with depression\/anxiety had used recreational psychedelics (p\u2009=\u20090.03) but were more likely to support government funded studies (p\u2009=\u20090.02). A minority (5%) of people with conditions (psychosis and bipolar disorder) that could be exacerbated by psilocybin thought it would be useful for them. One fifth of the total sample viewed psychedelics as addictive and unsafe even under medical supervision. Concerns included fear of adverse effects, lack of knowledge, insufficient research, illegality, and relapse if medications were discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The majority supported further research into psilocybin therapy. Younger people, those with previous recreational psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11845-021-02668-2","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T18:02:26Z","timestamp":1623780146000},"page":"1385-1397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Psychedelic perceptions: mental health service user attitudes to psilocybin therapy"],"prefix":"10.1007","volume":"191","author":[{"given":"Kate","family":"Corrigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Haran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"McCandliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Trant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Ledden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"O\u2019Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9545-0615","authenticated-orcid":false,"given":"John R.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"2668_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.2171","author":"D Nutt","year":"2020","unstructured":"Nutt D, Carhart-Harris R (2020) The current status of psychedelics in psychiatry. JAMA Psychiat. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.2171","journal-title":"JAMA Psychiat"},{"key":"2668_CR2","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00194","author":"DB Yaden","year":"2020","unstructured":"Yaden DB, Griffiths RR (2020) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science. https:\/\/doi.org\/10.1021\/acsptsci.0c00194","journal-title":"ACS Pharmacology & Translational Science"},{"key":"2668_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","author":"AK Davis","year":"2020","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2020) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiat"},{"issue":"15","key":"2668_CR4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402\u20131411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","journal-title":"N Engl J Med"},{"issue":"7","key":"2668_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/s2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619\u2013627. https:\/\/doi.org\/10.1016\/s2215-0366(16)30065-7","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"2668_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399\u2013408. https:\/\/doi.org\/10.1007\/s00213-017-4771-x","journal-title":"Psychopharmacology"},{"issue":"9","key":"2668_CR7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881119845793","volume":"33","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 33(9):1088\u20131101. https:\/\/doi.org\/10.1177\/0269881119845793","journal-title":"J Psychopharmacol"},{"issue":"12","key":"2668_CR8","doi-asserted-by":"publisher","first-page":"9791","DOI":"10.1007\/s11033-020-06009-x","volume":"47","author":"AJ DiVito","year":"2020","unstructured":"DiVito AJ, Leger RF (2020) Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. Mol Biol Rep 47(12):9791\u20139799. https:\/\/doi.org\/10.1007\/s11033-020-06009-x","journal-title":"Mol Biol Rep"},{"issue":"7","key":"2668_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen PO (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 26(7):994\u20131002. https:\/\/doi.org\/10.1177\/0269881112439253","journal-title":"J Psychopharmacol"},{"issue":"3","key":"2668_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29(3):289\u2013299. https:\/\/doi.org\/10.1177\/0269881114565144","journal-title":"J Psychopharmacol"},{"issue":"11","key":"2668_CR11","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67(11):1735\u20131740","journal-title":"J Clin Psychiatry"},{"key":"2668_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40519-020-01000-8","author":"MJ Spriggs","year":"2020","unstructured":"Spriggs MJ, Kettner H, Carhart-Harris RL (2020) Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. https:\/\/doi.org\/10.1007\/s40519-020-01000-8","journal-title":"Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity"},{"key":"2668_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00962-y","author":"EAD Schindler","year":"2020","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D\u2019Souza DC (2020) Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. https:\/\/doi.org\/10.1007\/s13311-020-00962-y","journal-title":"Neurotherapeutics"},{"issue":"1","key":"2668_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","volume":"73","author":"A Inserra","year":"2021","unstructured":"Inserra A, De Gregorio D, Gobbi G (2021) Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev 73(1):202\u2013277. https:\/\/doi.org\/10.1124\/pharmrev.120.000056","journal-title":"Pharmacol Rev"},{"key":"2668_CR15","doi-asserted-by":"publisher","DOI":"10.31234\/osf.io\/8vks6","author":"PJ Teixeira","year":"2021","unstructured":"Teixeira PJ, Johnson M, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner HRCH (2021) Psychedelics and health behavior change. J Psychopharmacol (in press). https:\/\/doi.org\/10.31234\/osf.io\/8vks6","journal-title":"J Psychopharmacol (in press)"},{"issue":"2","key":"2668_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"issue":"25","key":"2668_CR17","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35(25):2505\u20132511. https:\/\/doi.org\/10.1016\/0024-3205(84)90436-3","journal-title":"Life Sci"},{"issue":"3","key":"2668_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonz\u00e1lez-Maeso","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior. Neuron 53(3):439\u2013452. https:\/\/doi.org\/10.1016\/j.neuron.2007.01.008","journal-title":"Neuron"},{"key":"2668_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnins.2010.00036","volume":"4","author":"ET Weber","year":"2010","unstructured":"Weber ET, Andrade R (2010) Htr2a Gene and 5-HT(2A) Receptor expression in the cerebral cortex studied using genetically modified mice. Front Neurosci 4:36. https:\/\/doi.org\/10.3389\/fnins.2010.00036","journal-title":"Front Neurosci"},{"issue":"3","key":"2668_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.neuropharm.2011.01.015","volume":"61","author":"R Andrade","year":"2011","unstructured":"Andrade R (2011) Serotonergic regulation of neuronal excitability in the prefrontal cortex. Neuropharmacology 61(3):382\u2013386. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.015","journal-title":"Neuropharmacology"},{"key":"2668_CR21","doi-asserted-by":"publisher","unstructured":"Burt JB, Preller KH, Demirta\u015f M, Ji JL, Krystal JH, Vollenweider FX, Anticevic A, Murray JD (2021) Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD. bioRxiv:2021.2001.2031.429016. https:\/\/doi.org\/10.1101\/2021.01.31.429016","DOI":"10.1101\/2021.01.31.429016"},{"issue":"6","key":"2668_CR22","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL (2020) Structure of a hallucinogen-activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell 182(6):1574-1588.e1519. https:\/\/doi.org\/10.1016\/j.cell.2020.08.024","journal-title":"Cell"},{"issue":"4","key":"2668_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881120959609","volume":"35","author":"DS Stenb\u00e6k","year":"2020","unstructured":"Stenb\u00e6k DS, Madsen MK, Ozenne B, Kristiansen S, Burmester D, Erritzoe D, Knudsen GM, Fisher PM (2020) Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol 35(4):459\u2013468. https:\/\/doi.org\/10.1177\/0269881120959609","journal-title":"J Psychopharmacol"},{"key":"2668_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.043","author":"C Dong","year":"2021","unstructured":"Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, Azinfar A, Oh WC, Wetsel WC, Olson DE, Tian L (2021) Psychedelic-inspired drug discovery using an engineered biosensor. Cell. https:\/\/doi.org\/10.1016\/j.cell.2021.03.043","journal-title":"Cell"},{"key":"2668_CR25","doi-asserted-by":"publisher","unstructured":"Singleton SP, Luppi AI, Carhart-Harris RL, Cruzat J, Roseman L, Deco G, Kringelbach ML, Stamatakis EA, Kuceyeski A (2021) LSD flattens the brain\u2019s energy landscape: evidence from receptor-informed network control theory. bioRxiv:2021.2005.2014.444193. https:\/\/doi.org\/10.1101\/2021.05.14.444193","DOI":"10.1101\/2021.05.14.444193"},{"issue":"17","key":"2668_CR26","doi-asserted-by":"publisher","first-page":"e2022489118","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM (2021) Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci 118(17):e2022489118. https:\/\/doi.org\/10.1073\/pnas.2022489118","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2668_CR27","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1038\/s41598-017-05407-9","volume":"7","author":"JA Morales-Garcia","year":"2017","unstructured":"Morales-Garcia JA, de la Fuente RM, Alonso-Gil S, Rodriguez-Franco MI, Feilding A, Perez-Castillo A, Riba J (2017) The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep 7(1):5309. https:\/\/doi.org\/10.1038\/s41598-017-05407-9","journal-title":"Sci Rep"},{"issue":"4","key":"2668_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228(4):481\u2013491. https:\/\/doi.org\/10.1007\/s00221-013-3579-0","journal-title":"Exp Brain Res"},{"issue":"11","key":"2668_CR29","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23(11):3170\u20133182. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.022","journal-title":"Cell Rep"},{"key":"2668_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3008-z","author":"LP Cameron","year":"2020","unstructured":"Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE (2020) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. https:\/\/doi.org\/10.1038\/s41586-020-3008-z","journal-title":"Nature"},{"key":"2668_CR31","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00065","author":"C Ly","year":"2020","unstructured":"Ly C, Greb AC, Vargas MV, Duim WC, Grodzki ACG, Lein PJ, Olson DE (2020) Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth. ACS Pharmacology & Translational Science. https:\/\/doi.org\/10.1021\/acsptsci.0c00065","journal-title":"ACS Pharmacology & Translational Science"},{"key":"2668_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0718-8","author":"NL Mason","year":"2020","unstructured":"Mason NL, Kuypers KPC, M\u00fcller F, Reckweg J, Tse DHY, Toennes SW, Hutten N, Jansen JFA, Stiers P, Feilding A, Ramaekers JG (2020) Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. https:\/\/doi.org\/10.1038\/s41386-020-0718-8","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"2668_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH (2020) Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 21(11):611\u2013624. https:\/\/doi.org\/10.1038\/s41583-020-0367-2","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"2668_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/yco.0000000000000467","volume":"32","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL (2019) How do psychedelics work? Curr Opin Psychiatry 32(1):16\u201321. https:\/\/doi.org\/10.1097\/yco.0000000000000467","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"2668_CR35","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 7(1):13187. https:\/\/doi.org\/10.1038\/s41598-017-13282-7","journal-title":"Sci Rep"},{"key":"2668_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","volume":"142","author":"L Roseman","year":"2018","unstructured":"Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL (2018) Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology 142:263\u2013269. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.041","journal-title":"Neuropharmacology"},{"issue":"8","key":"2668_CR37","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"R Kraehenmann","year":"2015","unstructured":"Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX (2015) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry 78(8):572\u2013581. https:\/\/doi.org\/10.1016\/j.biopsych.2014.04.010","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2668_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/2045125316689030","volume":"7","author":"RG Dos Santos","year":"2017","unstructured":"Dos Santos RG, Bouso JC, Hallak JEC (2017) Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Ther Adv Psychopharmacol 7(4):141\u2013157. https:\/\/doi.org\/10.1177\/2045125316689030","journal-title":"Ther Adv Psychopharmacol"},{"key":"2668_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaa117","author":"P Leptourgos","year":"2020","unstructured":"Leptourgos P, Fortier-Davy M, Carhart-Harris R, Corlett PR, Dupuis D, Halberstadt AL, Kometer M, Kozakova E, Lar\u00d8i F, Noorani TN, Preller KH, Waters F, Zaytseva Y, Jardri R (2020) Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. Schizophr Bull. https:\/\/doi.org\/10.1093\/schbul\/sbaa117","journal-title":"Schizophr Bull"},{"key":"2668_CR40","doi-asserted-by":"publisher","unstructured":"Carhart-Harris RL, Wagner AC, Agrawal M, Kettner H, Rosenbaum JF, Gazzaley A, Nutt DJ, Erritzoe D (2021) Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? J Psychopharmacol (Oxford, England):2698811211008567. https:\/\/doi.org\/10.1177\/02698811211008567","DOI":"10.1177\/02698811211008567"},{"issue":"2","key":"2668_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/ipm.2020.94","volume":"38","author":"JR Kelly","year":"2021","unstructured":"Kelly JR, Crockett MT, Alexander L, Haran M, Baker A, Burke L, Brennan C, O\u2019Keane V (2021) Psychedelic science in post-COVID-19 psychiatry. Ir J Psychol Med 38(2):93\u201398. https:\/\/doi.org\/10.1017\/ipm.2020.94","journal-title":"Ir J Psychol Med"},{"issue":"12","key":"2668_CR42","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30(12):1268\u20131278. https:\/\/doi.org\/10.1177\/0269881116662634","journal-title":"J Psychopharmacol"},{"key":"2668_CR43","unstructured":"RANZCP (2020) The Royal Australian and New Zealand College of Psychiatrists (RANZCP). Therapeutic use of psychedelic substances.\u00a0https:\/\/www.ranzcp.org\/files\/resources\/college_statements\/clinical_memoranda\/cm-therapeutic-use-of-psychedelics.aspx"},{"key":"2668_CR44","doi-asserted-by":"publisher","unstructured":"Kelly JR, Baker A, Babiker M, Burke L, Brennan C, O\u2019Keane V (2019) The psychedelic renaissance: the next trip for psychiatry? Ir J Psychol Med 1\u20135. https:\/\/doi.org\/10.1017\/ipm.2019.39","DOI":"10.1017\/ipm.2019.39"},{"issue":"1","key":"2668_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt D, Erritzoe D, Carhart-Harris R (2020) Psychedelic Psychiatry\u2019s Brave New World. Cell 181(1):24\u201328. https:\/\/doi.org\/10.1016\/j.cell.2020.03.020","journal-title":"Cell"},{"key":"2668_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/hpja.454","author":"A Roche","year":"2020","unstructured":"Roche A, Kostadinov V, Chapman J, McEntee A (2020) Have decreases in young workers\u2019 risky drinking resulted in an increase in illicit drug use? Health Promot J Austr. https:\/\/doi.org\/10.1002\/hpja.454","journal-title":"Health Promot J Austr"},{"issue":"7","key":"2668_CR47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/ajad.12803","volume":"27","author":"JJ Palamar","year":"2018","unstructured":"Palamar JJ, Le A (2018) Trends in DMT and other tryptamine use among young adults in the United States. Am J Addict 27(7):578\u2013585. https:\/\/doi.org\/10.1111\/ajad.12803","journal-title":"Am J Addict"},{"key":"2668_CR48","doi-asserted-by":"publisher","first-page":"108071","DOI":"10.1016\/j.drugalcdep.2020.108071","volume":"212","author":"RA Yockey","year":"2020","unstructured":"Yockey RA, Vidourek RA, King KA (2020) Trends in LSD use among US adults: 2015\u20132018. Drug Alcohol Depend 212:108071. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108071","journal-title":"Drug Alcohol Depend"},{"key":"2668_CR49","unstructured":"Winstock AR, Timmermann C, Davis E, Maier LJ, Zhuparris A, Ferris JA, Barratt MJ, Kuypers KPC (2020) Global Drugs Survey (GDS) 2020 Psychedelics Key Findings Report"},{"key":"2668_CR50","unstructured":"U.S. Department of Health and Human Services SAaMHSAS, Center for Behavioral Health Statistics and Quality (2019) (2019) Key Substance Use and Mental Health Indicators in the United States: results from the 2018 National Survey on Drug Use and Health. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHNationalFindingsReport2018\/NSDUHNationalFindingsReport2018.pdf"},{"key":"2668_CR51","doi-asserted-by":"publisher","first-page":"108715","DOI":"10.1016\/j.drugalcdep.2021.108715","volume":"223","author":"B Killion","year":"2021","unstructured":"Killion B, Hai AH, Alsolami A, Vaughn MG, Sehun OhP, Salas-Wright CP (2021) LSD use in the United States: trends, correlates, and a typology of us. Drug Alcohol Depend 223:108715. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108715","journal-title":"Drug Alcohol Depend"},{"key":"2668_CR52","unstructured":"Addiction. EMCfDaD (2020) Impact of COVID-19 on patterns of drug use and drug-related harms in Europe, EMCDDA Trendspotter briefing"},{"key":"2668_CR53","unstructured":"Wales DMFftCSfEa (2019) Drugs misuse: findings from the 2018\/19 crime survey for England and Wales. https:\/\/www.gov.uk\/government\/statistics\/drug-misuse-findings-from-the-2018-to-2019-csew"},{"key":"2668_CR54","unstructured":"PHIRB (2011) National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch.Drug Use in Irelan"},{"key":"2668_CR55","doi-asserted-by":"publisher","unstructured":"Grant JE, Lust K, Chamberlain SR (2019) Hallucinogen use is associated with mental health and addictive problems and impulsivity in university students. Addict Behav Rep 10. https:\/\/doi.org\/10.1016\/j.abrep.2019.100228","DOI":"10.1016\/j.abrep.2019.100228"},{"issue":"2","key":"2668_CR56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1556\/2054.01.2017.008","volume":"1","author":"JI Wildberger","year":"2017","unstructured":"Wildberger JI, John CN, Hallock RM (2017) Perceptions of the medicinal value of hallucinogenic drugs among college students 1(2):50. https:\/\/doi.org\/10.1556\/2054.01.2017.008","journal-title":"Perceptions of the medicinal value of hallucinogenic drugs among college students"},{"issue":"6","key":"2668_CR57","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/nmd.0000000000000828","volume":"206","author":"BS Barnett","year":"2018","unstructured":"Barnett BS, Siu WO, Pope HG Jr (2018) A survey of American psychiatrists\u2019 attitudes toward classic hallucinogens. J Nerv Ment Dis 206(6):476\u2013480. https:\/\/doi.org\/10.1097\/nmd.0000000000000828","journal-title":"J Nerv Ment Dis"},{"key":"2668_CR58","unstructured":"Winstock AR, Johnson MW (2019) Global drugs survey: the psychedelic revolution in psychiatry and why patient opinion matters so much. https:\/\/www.globaldrugsurvey.com\/gds-2019\/gds2019-the-psychedelic-revolution-in-psychiatry-and-why-patient-opinion-matters-so-much\/"},{"key":"2668_CR59","unstructured":"Statement on open science and open praxis with psilocybin, MDMA, and similar substances (2017)\u00a0https:\/\/files.csp.org\/open"},{"key":"2668_CR60","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3672","author":"DB Yaden","year":"2020","unstructured":"Yaden DB, Yaden ME, Griffiths RR (2020) Psychedelics in psychiatry\u2014keeping the renaissance from going off the rails. JAMA Psychiat. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3672","journal-title":"JAMA Psychiat"},{"key":"2668_CR61","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00198","author":"MW Johnson","year":"2020","unstructured":"Johnson MW (2020) Consciousness, religion, and gurus: pitfalls of psychedelic medicine. ACS Pharmacology & Translational Science. https:\/\/doi.org\/10.1021\/acsptsci.0c00198","journal-title":"ACS Pharmacology & Translational Science"},{"key":"2668_CR62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40345-014-0020-y","volume":"3","author":"AG Szmulewicz","year":"2015","unstructured":"Szmulewicz AG, Valerio MP, Smith JM (2015) Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report. Int J Bipolar Disord 3:4\u20134. https:\/\/doi.org\/10.1186\/s40345-014-0020-y","journal-title":"Int J Bipolar Disord"},{"issue":"4","key":"2668_CR63","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/02791072.2017.1344898","volume":"49","author":"T Brown","year":"2017","unstructured":"Brown T, Shao W, Ayub S, Chong D, Cornelius C (2017) A Physician\u2019s attempt to self-medicate bipolar depression with N, N-dimethyltryptamine (DMT). J Psychoactive Drugs 49(4):294\u2013296. https:\/\/doi.org\/10.1080\/02791072.2017.1344898","journal-title":"J Psychoactive Drugs"},{"key":"2668_CR64","unstructured":"Abuse NIoD (2020) Substance Use in Women Research Report"},{"issue":"6","key":"2668_CR65","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/0269881120908004","volume":"34","author":"D Rosenbaum","year":"2020","unstructured":"Rosenbaum D, Weissman C, Anderson T, Petranker R, Dinh-Williams LA, Hui K, Hapke E (2020) Microdosing psychedelics: demographics, practices, and psychiatric comorbidities. J Psychopharmacol 34(6):612\u2013622. https:\/\/doi.org\/10.1177\/0269881120908004","journal-title":"J Psychopharmacol"},{"issue":"2","key":"2668_CR66","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/02791072.2019.1593561","volume":"51","author":"J Fadiman","year":"2019","unstructured":"Fadiman J, Korb S (2019) Might microdosing psychedelics be safe and beneficial? An initial exploration J Psychoactive Drugs 51(2):118\u2013122. https:\/\/doi.org\/10.1080\/02791072.2019.1593561","journal-title":"An initial exploration J Psychoactive Drugs"},{"issue":"9","key":"2668_CR67","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0269881119857204","volume":"33","author":"KP Kuypers","year":"2019","unstructured":"Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. J Psychopharmacol 33(9):1039\u20131057. https:\/\/doi.org\/10.1177\/0269881119857204","journal-title":"J Psychopharmacol"},{"issue":"2","key":"2668_CR68","doi-asserted-by":"publisher","first-page":"e0211023","DOI":"10.1371\/journal.pone.0211023","volume":"14","author":"V Polito","year":"2019","unstructured":"Polito V, Stevenson RJ (2019) A systematic study of microdosing psychedelics. PLoS ONE 14(2):e0211023. https:\/\/doi.org\/10.1371\/journal.pone.0211023","journal-title":"PLoS ONE"},{"issue":"2","key":"2668_CR69","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00213-018-5106-2","volume":"236","author":"T Anderson","year":"2019","unstructured":"Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS (2019) Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology 236(2):731\u2013740. https:\/\/doi.org\/10.1007\/s00213-018-5106-2","journal-title":"Psychopharmacology"},{"issue":"1","key":"2668_CR70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12954-019-0308-4","volume":"16","author":"T Anderson","year":"2019","unstructured":"Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E (2019) Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J 16(1):43. https:\/\/doi.org\/10.1186\/s12954-019-0308-4","journal-title":"Harm Reduct J"},{"issue":"10","key":"2668_CR71","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","volume":"86","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H (2019) Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiat 86(10):792\u2013800. https:\/\/doi.org\/10.1016\/j.biopsych.2019.05.019","journal-title":"Biol Psychiat"},{"issue":"4","key":"2668_CR72","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00213-018-5119-x","volume":"236","author":"S Yanakieva","year":"2019","unstructured":"Yanakieva S, Polychroni N, Family N, Williams LTJ, Luke DP, Terhune DB (2019) The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology 236(4):1159\u20131170. https:\/\/doi.org\/10.1007\/s00213-018-5119-x","journal-title":"Psychopharmacology"},{"issue":"3","key":"2668_CR73","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","volume":"237","author":"N Family","year":"2020","unstructured":"Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (2020) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology 237(3):841\u2013853. https:\/\/doi.org\/10.1007\/s00213-019-05417-7","journal-title":"Psychopharmacology"},{"key":"2668_CR74","doi-asserted-by":"publisher","unstructured":"Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D (2021) Self-blinding citizen science to explore psychedelic microdosing. eLife 10:e62878. https:\/\/doi.org\/10.7554\/eLife.62878","DOI":"10.7554\/eLife.62878"},{"key":"2668_CR75","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00192","author":"DE Olson","year":"2020","unstructured":"Olson DE (2020) The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology & Translational Science. https:\/\/doi.org\/10.1021\/acsptsci.0c00192","journal-title":"ACS Pharmacology & Translational Science"},{"key":"2668_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/da.23065","author":"NM Weston","year":"2020","unstructured":"Weston NM, Gibbs D, Bird CIV, Daniel A, Jelen LA, Knight G, Goldsmith D, Young AH, Rucker JJ (2020) Historic psychedelic drug trials and the treatment of anxiety disorders. Depress Anxiety. https:\/\/doi.org\/10.1002\/da.23065","journal-title":"Depress Anxiety"},{"key":"2668_CR77","unstructured":"Medicine USNLo (2021) The safety and efficacy of psilocybin in participants with treatment resistant depression (P-TRD) (ClinicalTrials.gov). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03775200?term=PSILOCYBIN"},{"key":"2668_CR78","unstructured":"Medicine USNLo (2021) A Study of Psilocybin for Major Depressive Disorder (MDD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03866174?term=PSILOCYBIN"},{"key":"2668_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot\u2019alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R, (2021) MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"key":"2668_CR80","doi-asserted-by":"publisher","unstructured":"Castellanos JP, Woolley C, Bruno KA, Zeidan F, Halberstadt A, Furnish T (2020) Chronic pain and psychedelics: a review and proposed mechanism of action. Regional Anesthesia & Pain Medicine:rapm-2020\u2013101273. https:\/\/doi.org\/10.1136\/rapm-2020-101273","DOI":"10.1136\/rapm-2020-101273"},{"issue":"1","key":"2668_CR81","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2307\/3479497","volume":"56","author":"A Watts","year":"1968","unstructured":"Watts A (1968) Psychedelics and Religious Experience. Calif Law Rev 56(1):74\u201385. https:\/\/doi.org\/10.2307\/3479497","journal-title":"Calif Law Rev"},{"issue":"4","key":"2668_CR82","doi-asserted-by":"publisher","first-page":"e0214377","DOI":"10.1371\/journal.pone.0214377","volume":"14","author":"RR Griffiths","year":"2019","unstructured":"Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R (2019) Survey of subjective \u201cGod encounter experiences\u201d: comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE 14(4):e0214377. https:\/\/doi.org\/10.1371\/journal.pone.0214377","journal-title":"PLoS ONE"},{"key":"2668_CR83","volume-title":"Plants of the gods: their sacred, healing, and hallucinogenic powers","author":"RE Schultes","year":"2001","unstructured":"Schultes RE, Hofmann A, R\u00e4tsch C (2001) Plants of the gods: their sacred, healing, and hallucinogenic powers. Healing Arts Press, Rochester, Vt"},{"key":"2668_CR84","unstructured":"Guzm\u00e1n G (1983) The genus Psilocybe : a systematic revision of the known species including the history, distribution, and chemistry of the hallucinogenic species. J. Cramer, Vaduz [Liechtenstein]"},{"issue":"9566","key":"2668_CR85","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/s0140-6736(07)60464-4","volume":"369","author":"D Nutt","year":"2007","unstructured":"Nutt D, King LA, Saulsbury W, Blakemore C (2007) Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369(9566):1047\u20131053. https:\/\/doi.org\/10.1016\/s0140-6736(07)60464-4","journal-title":"Lancet"},{"issue":"7","key":"2668_CR86","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/0269881119841569","volume":"33","author":"Y Bonomo","year":"2019","unstructured":"Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, Egerton-Warburton D, Karro J, Kim C, Lenton S, Lubman DI, Pastor A, Rundle J, Ryan J, Gordon P, Sharry P, Nutt D, Castle D (2019) The Australian drug harms ranking study. J Psychopharmacol 33(7):759\u2013768. https:\/\/doi.org\/10.1177\/0269881119841569","journal-title":"J Psychopharmacol"},{"key":"2668_CR87","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142:143\u2013166. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012","journal-title":"Neuropharmacology"},{"issue":"8","key":"2668_CR88","doi-asserted-by":"publisher","first-page":"e63972","DOI":"10.1371\/journal.pone.0063972","volume":"8","author":"TS Krebs","year":"2013","unstructured":"Krebs TS, Johansen P\u00d8 (2013) Psychedelics and mental health: a population study. PLoS ONE 8(8):e63972. https:\/\/doi.org\/10.1371\/journal.pone.0063972","journal-title":"PLoS ONE"},{"key":"2668_CR89","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","volume":"142","author":"JJH Rucker","year":"2018","unstructured":"Rucker JJH, Iliff J, Nutt DJ (2018) Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology 142:200\u2013218. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.040","journal-title":"Neuropharmacology"},{"key":"2668_CR90","doi-asserted-by":"publisher","first-page":"h2902","DOI":"10.1136\/bmj.h2902","volume":"350","author":"JJ Rucker","year":"2015","unstructured":"Rucker JJ (2015) Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. BMJ 350:h2902. https:\/\/doi.org\/10.1136\/bmj.h2902","journal-title":"BMJ"},{"issue":"8","key":"2668_CR91","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrn3530","volume":"14","author":"DJ Nutt","year":"2013","unstructured":"Nutt DJ, King LA, Nichols DE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci 14(8):577\u2013585. https:\/\/doi.org\/10.1038\/nrn3530","journal-title":"Nat Rev Neurosci"},{"key":"2668_CR92","unstructured":"Policy GCOD (2021)\u00a0https:\/\/www.globalcommissionondrugs.org\/reports"},{"issue":"2","key":"2668_CR93","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.drugpo.2011.02.002","volume":"22","author":"D Werb","year":"2011","unstructured":"Werb D, Rowell G, Guyatt G, Kerr T, Montaner J, Wood E (2011) Effect of drug law enforcement on drug market violence: a systematic review. Int J Drug Policy 22(2):87\u201394. https:\/\/doi.org\/10.1016\/j.drugpo.2011.02.002","journal-title":"Int J Drug Policy"},{"key":"2668_CR94","unstructured":"Winstock A, Barratt M, Ferris JLM (2017) Global Drug Survey"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-021-02668-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-021-02668-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-021-02668-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T23:54:46Z","timestamp":1653609286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-021-02668-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2668"],"URL":"https:\/\/doi.org\/10.1007\/s11845-021-02668-2","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tallaght University Hospital\/St. James\u2019s Hospital Joint Research Ethics Committee and the St. Patrick\u2019s Hospital approved this study. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committee on human experimentation with the Helsinki Declaration of 1975, as revised in 2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"VO\u2019K is supported by the Health Research Board (HRB) through HRB Grant code: 201651.12553 and the Meath Foundation, Tallaght University Hospital. She is the Principal Investigator (PI) on the COMPASS trials (COMP001, 003, 004) in Ireland. JK is sub-PI on the COMPASS trials (COMP 001, 003, 004) in Ireland. All other authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}